Skip to main content
main-content

The independent medical news service

Breast cancer

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1814017
SABCS 2018; San Antonio, Texas, USA; 4–8 December

03-12-2018 | Oncology | News | Article

approvalsWatch

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

08-11-2018 | Oncology | Main feed | News

TRAIN-2 questions neoadjuvant anthracycline use for HER2-positive breast cancer

Carboplatin plus taxane neoadjuvant chemotherapy may be sufficient for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer, findings from the TRAIN-2 study suggest.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30570-9

06-11-2018 | Oncology | Main feed | News

NCRI 2018

Early risers may have reduced breast cancer risk

Women who function better earlier in the day, so-called morning people, are less likely to develop breast cancer than those who consider themselves night owls, suggests a Mendelian randomization analysis.

Source:

NCRI 2018; Glasgow, UK; 4–6 November

06-11-2018 | Oncology | Main feed | News

NCRI 2018

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

Source:

NCRI 2018; Glasgow, UK

05-11-2018 | Breast cancer | Main feed | News

Epigenetic therapy shows promise for HR-positive advanced breast cancer

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.

Source:

ESMO 2018; Munich, Germany; 19–23 October

25-10-2018 | Oncology | News | Article

ESMO 2018

Atezolizumab combination improves advanced TNBC survival

First-line treatment with the programmed cell death ligand 1 inhibitor atezolizumab plus nab-paclitaxel has achieved a significant progression-free survival advantage over taxane chemotherapy alone in patients with metastatic triple-negative breast cancer, research suggests.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1809615
ESMO 2018; Munich, Germany; 19–23 October

23-10-2018 | Oncology | News | Article

ESMO 2018 in brief

Serum testing reveals tamoxifen therapy nonadherence

Serum analysis suggests that within a year of beginning endocrine therapy after early breast cancer treatment, around one in six premenopausal women are no longer adherent to tamoxifen.

Source:

ESMO 2018 Congress; Munich, Germany: 19–23 October 2018
Ann Oncol 2018; 29: Supplement 8, abstract 185O_PR

12-10-2018 | Breast cancer | News | Article

Editor's pick

Endocrine therapy impacts cardiovascular risk in women with breast cancer

Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.

Source:

BMJ 2018; 363: k3845

11-10-2018 | Breast cancer | News | Article

News in brief

Postmenopausal weight loss linked to reduced breast cancer risk

Postmenopausal women who lose weight have a lower risk for breast cancer than those who maintain a stable weight, report researchers.

10-10-2018 | Oncology | News | Article

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.

Source:

Cancer 2018; doi:10.1002/cncr.31760
JAMA Network Open 2018; 1: e183023

09-10-2018 | Breast cancer | News | Article

Lurbinectedin activity shown in metastatic breast cancer

Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1/2-mutated metastatic breast cancer, phase II study data show.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6558

20-09-2018 | Oncology | Main feed | News

Early atezolizumab results point to potential role in metastatic TNBC care

Phase I trial findings suggest that patients with metastatic triple-negative breast cancer might benefit from treatment with the programmed cell death ligand 1 inhibitor atezolizumab.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4224

18-09-2018 | Oncology | Main feed | News

approvalsWatch

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

03-09-2018 | Breast cancer | News | Article

Editor's pick

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.

Source:

N Engl J Med 2018; 379: 753–763
Ann Oncol 2018; doi:10.1093/annonc/mdy257

31-08-2018 | Breast cancer | News | Article

In other news: Breast cancer treatment effects

The focus this month is on early and late treatment effects in patients with breast cancer, including effects on endometrial cancer risk, cardiotoxicity, and skin toxicity.

28-08-2018 | Breast cancer | News | Article

Adding pertuzumab to trastuzumab effective for HER2-positive breast cancer

Adding pertuzumab to trastuzumab plus an aromatase inhibitor may be effective for patients with human HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer, a phase II trial suggests.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2017.76.7863

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy263

20-08-2018 | Breast cancer | News | Article

Adjuvant radiotherapy may improve DCIS outcomes

Canadian researchers have found that the use of radiotherapy after surgery for ductal carcinoma in situ leads to an improvement in breast cancer-specific survival, possibly due to its systemic effects.

Source:

JAMA Network Open 2018; 1: e181100

10-08-2018 | Oncology | News | Article

Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy229
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.2028

image credits